The Capital Allocation Pain Point: Balancing R&D Burn with Defensible IP to Maximize ROI
In the relentless race to bring groundbreaking pharmaceuticals to market, biotech and pharma companies are caught in a high-stakes balancing act. On one side, the relentless push to innovate—ramping up R&D investments to discover the next blockbust…
The Capital Allocation Pain Point: Balancing R&D Burn with Defensible IP to Maximize ROI Read Post »
